Latest Insider Transactions at Karyopharm Therapeutics Inc. (KPTI)
This section provides a real-time view of insider transactions for Karyopharm Therapeutics Inc. (KPTI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Karyopharm Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Karyopharm Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2023
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
2,802
-1.7%
|
$8,406
$3.04 P/Share
|
|
Feb 15
2023
|
Stuart Poulton EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,869
-2.8%
|
$17,607
$3.19 P/Share
|
|
Feb 06
2023
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
4,141
-2.46%
|
$12,423
$3.4 P/Share
|
|
Feb 06
2023
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,950
-0.65%
|
$11,850
$3.4 P/Share
|
|
Jan 04
2023
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,922
-0.64%
|
$11,766
$3.27 P/Share
|
|
Dec 05
2022
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,490
-0.57%
|
$17,450
$5.17 P/Share
|
|
Nov 04
2022
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,493
-0.56%
|
$13,972
$4.54 P/Share
|
|
Oct 04
2022
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,488
-0.56%
|
$17,440
$5.87 P/Share
|
|
Sep 08
2022
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,479
-0.28%
|
$17,395
$5.25 P/Share
|
|
Aug 31
2022
|
Stephen Mitchener SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+22.09%
|
-
|
|
Aug 31
2022
|
Michael Mano SVP, General Counsel&Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+19.42%
|
-
|
|
Aug 31
2022
|
Michael Mason EVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+15.11%
|
-
|
|
Aug 31
2022
|
Sohanya Roshan Cheng EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.01%
|
-
|
|
Aug 11
2022
|
Barry E Greene |
BUY
Exercise of conversion of derivative security
|
Direct |
7,576
+35.77%
|
$7,576
$1.49 P/Share
|
|
Aug 04
2022
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
2,314
-0.37%
|
$9,256
$4.48 P/Share
|
|
Jul 08
2022
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
2,115
-0.34%
|
$10,575
$5.18 P/Share
|
|
Jun 13
2022
|
Sohanya Roshan Cheng EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,551
-0.85%
|
$7,755
$5.27 P/Share
|
|
Jun 10
2022
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
1,307
-0.08%
|
$7,842
$6.0 P/Share
|
|
Jun 09
2022
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
211,500
-10.92%
|
$1,269,000
$6.18 P/Share
|
|
Jun 08
2022
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
325,977
-14.4%
|
$1,955,862
$6.5 P/Share
|
|
Jun 07
2022
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
2,542
-0.4%
|
$12,710
$5.76 P/Share
|
|
Jun 03
2022
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
601
-0.22%
|
$3,606
$6.06 P/Share
|
|
May 04
2022
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
28,502
-2.15%
|
$171,012
$6.25 P/Share
|
|
Apr 29
2022
|
Reshma Rangwala EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+50.0%
|
-
|
|
Mar 29
2022
|
Sharon Shacham Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+5.89%
|
-
|
|
Feb 28
2022
|
Michael Mano SVP, General Counsel&Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
63,000
+50.0%
|
-
|
|
Feb 28
2022
|
Richard A. Paulson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
288,750
+30.37%
|
-
|
|
Feb 28
2022
|
Sohanya Roshan Cheng EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,000
+47.86%
|
-
|
|
Feb 28
2022
|
Stephen Mitchener SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,250
+48.31%
|
-
|
|
Feb 28
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
6,226
-0.69%
|
$62,260
$10.24 P/Share
|
|
Feb 28
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
6,226
-0.86%
|
$62,260
$10.24 P/Share
|
|
Feb 28
2022
|
Michael Kauffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+2.83%
|
-
|
|
Feb 28
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,226
-0.86%
|
$62,260
$10.24 P/Share
|
|
Feb 28
2022
|
Sharon Shacham Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
21,000
+2.83%
|
-
|
|
Feb 28
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,226
-0.69%
|
$62,260
$10.24 P/Share
|
|
Feb 28
2022
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
2,398
-1.69%
|
$23,980
$10.24 P/Share
|
|
Feb 28
2022
|
Michael Mason EVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
88,200
+38.4%
|
-
|
|
Feb 28
2022
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
1,663
-0.98%
|
$16,630
$10.24 P/Share
|
|
Feb 28
2022
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,250
+28.65%
|
-
|
|
Feb 17
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
9,088
-0.99%
|
$109,056
$12.12 P/Share
|
|
Feb 17
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
9,079
-1.28%
|
$108,948
$12.12 P/Share
|
|
Feb 17
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
9,079
-1.28%
|
$108,948
$12.12 P/Share
|
|
Feb 17
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,088
-0.99%
|
$109,056
$12.12 P/Share
|
|
Feb 17
2022
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
2,929
-2.8%
|
$35,148
$12.12 P/Share
|
|
Feb 17
2022
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,306
-1.0%
|
$15,672
$12.12 P/Share
|
|
Feb 07
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,764
-0.95%
|
$60,876
$9.86 P/Share
|
|
Feb 07
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,707
-0.73%
|
$60,363
$9.86 P/Share
|
|
Feb 07
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
6,707
-0.73%
|
$60,363
$9.86 P/Share
|
|
Feb 07
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
6,764
-0.95%
|
$60,876
$9.86 P/Share
|
|
Feb 07
2022
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
3,947
-6.89%
|
$35,523
$9.86 P/Share
|